Bismuth, moxifloxacin, tetracycline, lansoprazole quadruple first line therapy for eradication of H. pylori: A prospective study

Clin Res Hepatol Gastroenterol. 2013 Nov;37(5):527-9. doi: 10.1016/j.clinre.2012.10.014. Epub 2013 Jan 9.
No abstract available

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Antacids / therapeutic use
  • Anti-Bacterial Agents / therapeutic use
  • Aza Compounds / therapeutic use*
  • Drug Therapy, Combination
  • Endoscopy, Gastrointestinal
  • Female
  • Fluoroquinolones
  • Helicobacter Infections / drug therapy*
  • Helicobacter pylori
  • Humans
  • Lansoprazole / therapeutic use*
  • Male
  • Medication Adherence
  • Middle Aged
  • Moxifloxacin
  • Organometallic Compounds / therapeutic use*
  • Prospective Studies
  • Proton Pump Inhibitors / therapeutic use
  • Quinolines / therapeutic use*
  • Tetracycline / therapeutic use*
  • Young Adult

Substances

  • Antacids
  • Anti-Bacterial Agents
  • Aza Compounds
  • Fluoroquinolones
  • Organometallic Compounds
  • Proton Pump Inhibitors
  • Quinolines
  • Lansoprazole
  • Tetracycline
  • bismuth tripotassium dicitrate
  • Moxifloxacin